NR3C2 and hypertensive disorder: More than 10% of hypertensive patients have raised aldosterone levels [111], and drugs that block the mineralocorticoid receptor (MR), the main target receptor of aldosterone, are used to treat hypertension that is resistant to ACE inhibition and AT1R antagonism [112].